Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term therapeutic use. Found 398 abstracts

no pagination
Langer CJ. Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?. Drugs Aging. 2008 Jan;25(3):209-18.
Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Lesniewski-Kmak K, Smakal M, Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB, Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.
Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?. Clinical lung cancer. 2008 Mar;9(2):85-91.
Mehra R, Cohen RB. New agents in the treatment for malignancies of the salivary and thyroid glands. Hematol Oncol Clin North Am. 2008 Dec;22(6):1279-95, xi.   PMCID: PMC2659655
Mehta RS, Chwistek M. Bisphosphonates and osteonecrosis of the jaw #196. J Palliat Med. 2008 Sep;11(7):1039-40.
Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ, Gynecologic Oncology G. Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group. Gynecol Oncol. 2008 Sep;110(3):329-35.   PMCID: PMC2577579
Ozols RF. Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer. Advances in experimental medicine and biology. 2008 Jan;622:131-43.
Parmar MK, Barthel FM, Sydes M, Langley R, Kaplan R, Eisenhauer E, Brady M, James N, Bookman MA, Swart AM, Qian W, Royston P. Speeding up the evaluation of new agents in cancer. Journal of the National Cancer Institute. 2008 Sep 03;100(17):1204-14.   PMCID: PMC2528020
Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, Schilder RJ, von Mehren M, Godwin AK, Yeung AT. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics. 2008 May;5(3-4):137-49.
Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer. 2008 Nov 04;99(9):1415-25.   PMCID: PMC2576487
Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies. Clin Cancer Res. 2008 Feb;14(3):875-82.   PMCID: PMC2643368
Sanborn RE, Lally BE. Adjuvant therapy for non-small cell lung cancer with mediastinal nodal involvement. Thorac Surg Clin. 2008 Nov;18(4):423-35.
Sarna L, Swann S, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Byhardt R, Wasserman T, Movsas B. Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008 Dec;72(5):1378-84.
Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Advances in experimental medicine and biology. 2008 Jan;630:206-19.
Small W, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008 Feb 20;26(6):942-7.
Swaby RF, Jordan VC. Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer. Clin Breast Cancer. 2008 Apr;8(2):124-33.
Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M, Godwin AK. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8387-92.   PMCID: PMC2448846
Uzzo RG, Haas NB, Crispen PL, Kolenko VM. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer. Cancer. 2008 Apr 15;112(8):1660-71.
von Mehren M, Schilder RJ, Cheng JD, Temmer E, Cardoso TM, Renshaw FG, Bayever E, Zannikos P, Yuan Z, Cohen RB. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol. 2008 Oct;19(10):1802-9.   PMCID: PMC2598415
Wagman LD, Baird MF, Bennett CL, Bockenstedt PL, Cataland SR, Fanikos J, Fogarty PF, Goldhaber SZ, Grover TS, Haire W, Hassoun H, Hutchinson S, Jahanzeb M, Lee J, Linenberger ML, Millenson MM, Ortel TL, Salem R, Smith JL, Streiff MB, Vedantham S, National Comprehensive Cancer N. Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008 Sep;6(8):716-53.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term therapeutic use

therapeutic use Female drug therapy Male Antineoplastic Agents therapy pathology administration & dosage Treatment Outcome Clinical Trials as Topic Aged Non-Small-Cell Lung Carcinoma Lung Neoplasms metabolism physiology Neoplasms Antineoplastic Combined Chemotherapy Protocols Ovarian Neoplasms Carboplatin Middle Aged 80 and over Aged Neoplasm Staging adverse effects Adult Hormonal Antineoplastic Agents Apoptosis immunology United States Neoplasm Drug Resistance effects methods adverse drug effects Adjuvant Chemotherapy Paclitaxel pharmacology Breast Neoplasms Tumor Cell Line Survival Analysis epidemiology radiotherapy Combined Modality Therapy antagonists & inhibitors Disease-Free Survival erbB-2 Receptor pharmacokinetics Mice prevention & control analogs & derivatives analogs & Pyrimidines Inbred ICR Mice Proto-Oncogene Proteins c-akt derivatives Platelet-Derived Growth Factor alpha Receptor drug blood surgery Polyglutamic Acid mortality Piperazines Prostatic Neoplasms genetics physiopathology diagnosis Quality of Life Drug Dose-Response Relationship complications Dioxoles Sexual Behavior Proto-Oncogene Proteins c-kit Mutation Research Design Estrogen Receptors Apoptosis Regulatory Proteins Radiation-Protective Agents Tetrahydroisoquinolines Socioeconomic Factors analysis Pneumonectomy Deglutition Radioimmunotherapy Dimerization Age Factors Polyethylene Glycols Astatine Gene Amplification Time Factors Gene Expression Profiling Risk Assessment CA-19-9 Antigen Estrogen Replacement Therapy secondary Amifostine Salivary Gland Neoplasms Biological Tumor Markers Small Interfering RNA Cell Proliferation Drug Delivery Systems induced Drug Approval Jaw Adjuvant Radiotherapy Peptide Fragments IGF Type 1 Receptor chemically induced Fallopian Tube Neoplasms Tissue Distribution Antineoplastic Protocols United States Food and Drug Administration Weight Loss Nausea Mediastinum enzymology Pancreatic Neoplasms Gynecologic Surgical Procedures Doxorubicin Nude Mice Drug Interactions Follow-Up Studies Biological Models Pyrroles Randomized Controlled Trials as Topic Osteonecrosis Inbred BALB C Mice Conformal Radiotherapy Gene Silencing Vomiting Deoxycytidine Diphosphonates Survival Rate Feasibility Studies Phase II Clinical Trials as Topic Epidermal Growth Factor Receptor Neoplasm Antigens Neoplastic Gene Expression Regulation Sample Size Phase III Clinical Trials as Topic Radiotherapy Hypercalcemia Cell Death Retrospective Studies chemically Mitogen-Activated Protein Kinase Kinases Antineoplastic Antimetabolites Gastrointestinal Stromal Tumors Heterologous Transplantation Thromboembolism Mass Spectrometry trends
Last updated on Friday, January 03, 2020